Analysis of the effectiveness of the combination of bevacizumab and irinotecan for the treatment of glial tumors

Authors

DOI:

https://doi.org/10.33448/rsd-v11i1.25135

Keywords:

Bevacizumab; Irinotecan; Glial tumors; Efficacy.

Abstract

Glial tumors, or gliomas, are the most common type of brain tumor and have a high incidence, most of which are diffuse and prone to extensive infiltration into the brain parenchyma, causing tumor recurrence. High-grade gliomas, such as glioblastomas, are highly angiogenic and have high levels of proangiogenic factors, such as vascular endothelial growth factor (VEGF), essential for tumor neovascularization. The target to inhibit VEGF is bevacizumab, a humanized monoclonal antibody, with association with irinotecan, a topoisomerase I inhibitor. Thus, the objective of the following review is to analyze the effectiveness of the combination of bevacizumab and irinotecan for the treatment of glial tumors . This is a systematic literature review that used the PubMed, SciELO and Google Scholar platforms as a database for researching scientific articles, with a time frame between 2016 and 2021, in English. According to the search engine, 3 results were found after the exclusion criteria in PubMed and Google Scholar databases. Therefore, it was found that the combined chemotherapy of bevacizumab and irinotecan is effective in the treatment of glial tumors, moreover, the combination of both drugs has a higher overall survival rate than the isolated therapy of the antiangiogenic bevacizumab.

References

Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J., & Khasraw, M. (2018). Anti‐angiogenic therapy for high‐grade glioma. Cochrane Database of Systematic Reviews, (11).

Bergman, D., Modh, A., Schultz, L., Snyder, J., Mikkelsen, T., Shah, M., ... & Walbert, T. (2020). Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. Journal of neuro-oncology, 148, 353-361.

Davis M. E. (2018). Epidemiology and Overview of Gliomas. Seminars in oncology nursing, 34(5), 420–429. https://doi.org/10.1016/j.soncn.2018.10.001

de Man, F. M., Goey, A., van Schaik, R., Mathijssen, R., & Bins, S. (2018). Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clinical pharmacokinetics, 57(10), 1229–1254. https://doi.org/10.1007/s40262-018-0644-7

Dong, J., Meng, X., Li, S., Chen, Q., Shi, L., Jiang, C., & Cai, J. (2019). Risk of adverse vascular events in patients with malignant glioma treated with bevacizumab plus irinotecan: A systematic review and meta-analysis. World neurosurgery, 130, e236-e243.

Figueiras, F. N., Duarte, M. L., & Santos, L. R. dos. (2020). Cerebellar pilocytic astrocytoma: literature review and case report of a young patient with anatomopathological correlation. Research, Society and Development, 9(7), e405974115. https://doi.org/10.33448/rsd-v9i7.4115

Li, Y., Ali, S., Clarke, J., & Cha, S. (2017). Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. Brain tumor research and treatment, 5(1), 1–9. https://doi.org/10.14791/btrt.2017.5.1.1

Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018). Current state of immunotherapy for glioblastoma. Nature reviews. Clinical oncology, 15(7), 422–442. https://doi.org/10.1038/s41571-018-0003-5

McBain, C., Lawrie, T. A., Rogozińska, E., Kernohan, A., Robinson, T., & Jefferies, S. (2021). Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. The Cochrane database of systematic reviews, 5(1), CD013579. https://doi.org/10.1002/14651858.CD013579.pub2

Nayak, L., & Reardon, D. A. (2017). High-grade Gliomas. Continuum (Minneapolis, Minn.), 23(6, Neuro-oncology), 1548–1563. https://doi.org/10.1212/CON.0000000000000554

Norden, A. D., & Wen, P. Y. (2006). Glioma therapy in adults. The neurologist, 12(6), 279–292. https://doi.org/10.1097/01.nrl.0000250928.26044.47

Omuro, A., & DeAngelis, L. M. (2013). Glioblastoma and other malignant gliomas: a clinical review. JAMA, 310(17), 1842–1850. https://doi.org/10.1001/jama.2013.280319

Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., Wrensch, M. R., & Barnholtz-Sloan, J. S. (2014). The epidemiology of glioma in adults: a "state of the science" review. Neuro-oncology, 16(7), 896–913. https://doi.org/10.1093/neuonc/nou087

Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S. M., & Barnholtz-Sloan, J. S. (2015). Epidemiology of gliomas. Cancer treatment and research, 163, 1–14. https://doi.org/10.1007/978-3-319-12048-5_1

Perry, A., & Wesseling, P. (2016). Histologic classification of gliomas. Handbook of clinical neurology, 134, 71–95. https://doi.org/10.1016/B978-0-12-802997-8.00005-0

Sandes , V. dos A. ., Dantas, R. L. ., Porto, R. L. S. ., Reis , F. F. P. ., Sousa , D. S. de ., Lima, S. O. ., Marcena, S. L. S. ., & Reis, F. P. (2020). The occurrence of tumors of the central nervous system in the state of Sergipe from 2008 to 2017. Research, Society and Development, 9(11), e3439119673. https://doi.org/10.33448/rsd-v9i11.9673

Seystahl, K., Wick, W., & Weller, M. (2016). Therapeutic options in recurrent glioblastoma--An update. Critical reviews in oncology/hematology, 99, 389–408. https://doi.org/10.1016/j.critrevonc.2016.01.018

Stylli, S. S., Luwor, R. B., Ware, T. M., Tan, F., & Kaye, A. H. (2015). Mouse models of glioma. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 22(4), 619–626. https://doi.org/10.1016/j.jocn.2014.10.013

Wang, T., & Mehta, M. P. (2019). Low-Grade Glioma Radiotherapy Treatment and Trials. Neurosurgery clinics of North America, 30(1), 111–118. https://doi.org/10.1016/j.nec.2018.08.008

Wesseling, P., & Capper, D. (2018). WHO 2016 Classification of gliomas. Neuropathology and applied neurobiology, 44(2), 139–150. https://doi.org/10.1111/nan.12432

Xiong, L., Wang, F., & Qi Xie, X. (2019). Advanced treatment in high-grade gliomas. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 24(2), 424–430.

Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020). Immunotherapy for glioma: Current management and future application. Cancer letters, 476, 1–12. https://doi.org/10.1016/j.canlet.2020.02.002

Published

09/01/2022

How to Cite

FONSECA, G. S. G. B. .; LEITE, M. J. F. L. .; COSTA, A. C. N. .; ANDRADE, P. P. .; FREIRE, V. M. L. M. .; MARINHO, L. C. O. .; LIMA, P. de L. .; PACHECO, L. O. P. L. .; BONFIM, L. L. .; AZEVEDO, P. G. de .; BRITTO, F. A. L. C. de .; REIS, L. L. T. .; VIEIRA, I. C. .; MACEDO, G. de S. .; MACEDO, G. M. L. B. .; MESQUITA NETO, A. R. .; BRITO, A. do R. .; PENHA, E. C. da S. .; GUIMARÃES, J. V. A. .; PEREIRA, R. E. L. .; MURAD, L. M. de A. .; OLIVEIRA, R. M. S. .; PRAZERES, J. S. .; COSTA, D. B. .; SILVA, R. L.; SANTOS, A. C. .; GARCIA, A. C. R. . Analysis of the effectiveness of the combination of bevacizumab and irinotecan for the treatment of glial tumors. Research, Society and Development, [S. l.], v. 11, n. 1, p. e37911125135, 2022. DOI: 10.33448/rsd-v11i1.25135. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/25135. Acesso em: 13 nov. 2024.

Issue

Section

Health Sciences